SCHEMBL6998917

SCHEMBL6998917

Cc1ccc2c(c1)NC(=O)c1c(sc3cc(C)ccc13)N2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1G1 Q9HCP0 1/20 0.46
ROS1 P08922 1/20 0.41
CDK5 Q00535 1/20 0.41
ACVR1 Q04771 1/20 0.41
LRRK2 Q5S007 1/20 0.41
MAPT P10636 6/20 0.41
MCL1 Q07820 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
NPC1 O15118 2/20 0.41
GAA P10253 2/20 0.41
RAB9A P51151 2/20 0.41
CYP2C9 P11712 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
BCL2L1 Q07817 1/20 0.35
EPHX2 P34913 1/20 0.35
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CAMK2B Q13554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6992029 0.91 ACVR1 (0.48) CSNK1G1ROS1CDK5ACVR1LRRK2
SCHEMBL6988596 0.91 CSNK1G1 (0.41) CSNK1G1ROS1CDK5ACVR1LRRK2
SCHEMBL6998266 0.91 CSNK1G1 (0.38) CSNK1G1ROS1CDK5ACVR1LRRK2
SCHEMBL6994996 0.89 CSNK1G1 (0.50) CSNK1G1ROS1CDK5ACVR1LRRK2
SCHEMBL6998420 0.89 CSNK1G1 (0.50) CSNK1G1ROS1CDK5ACVR1LRRK2
SCHEMBL6993139 0.80 CSNK1G1 (0.38) CSNK1G1ROS1CDK5ACVR1LRRK2
SCHEMBL6998771 0.80 CDK5 (0.48) CSNK1G1ROS1CDK5ACVR1LRRK2
SCHEMBL6990964 0.80 MAPT (0.40) LRRK2MAPTALDH1A1CYP1A2CYP2C19
SCHEMBL6992702 0.76 TGM2 (0.37) CDK5LRRK2MAPTALDH1A1CDK4
SCHEMBL6994826 0.75 CHEK1 (0.47) CDK5ACVR1LRRK2MAPTMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP claimed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US claimed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP claimed
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT CSNK1G1 1141/4885ROS1 3645/4885CDK5 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.